Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibit… Read more
Market Cap & Net Worth: Ascentage Pharma Group International (AAPG)
Ascentage Pharma Group International (NASDAQ:AAPG) has a market capitalization of $2.27 Billion ($2.27 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4653 globally and #2888 in its home market, demonstrating a 3.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ascentage Pharma Group International's stock price $24.40 by its total outstanding shares 92963369 (92.96 Million).
Ascentage Pharma Group International Market Cap History: 2025 to 2026
Ascentage Pharma Group International's market capitalization history from 2025 to 2026. Data shows growth from $2.44 Billion to $2.27 Billion (0.00% CAGR).
Index Memberships
Ascentage Pharma Group International is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.10% | #121 of 976 |
Weight: Ascentage Pharma Group International's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ascentage Pharma Group International Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ascentage Pharma Group International's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AAPG by Market Capitalization
Companies near Ascentage Pharma Group International in the global market cap rankings as of March 18, 2026.
Key companies related to Ascentage Pharma Group International by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Ascentage Pharma Group International Historical Marketcap From 2025 to 2026
Between 2025 and today, Ascentage Pharma Group International's market cap moved from $2.44 Billion to $ 2.27 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.27 Billion | -7.01% |
| 2025 | $2.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ascentage Pharma Group International was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.27 Billion USD |
| MoneyControl | $2.27 Billion USD |
| MarketWatch | $2.27 Billion USD |
| marketcap.company | $2.27 Billion USD |
| Reuters | $2.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.